DDInter624 DDInter1376
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatitis
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease)
Efavirenz (Compound) binds CYP2C19 (Gene)
Efavirenz (Compound) upregulates IKBKB (Gene)
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Efavirenz (Compound) downregulates POLR2I (Gene)
Efavirenz (Compound) causes Hepatitis (Side Effect)